Somy Cherian

Somy Cherian

Auto-generated profile, based on publicly available information

Somy Cherian

Centre for Arthritis and Rheumatism Excellence, Nettoor, Kochi, India

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2021 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
SCSomy Cherian
Somy Cherian
APAby Paul
Aby Paul
SASakir Ahmed
Sakir Ahmed
BABazil Alias
Bazil Alias
MMManesh Manoj
Manesh Manoj
PSPadmanabha Shenoy
Padmanabha Shenoy

30 December 2022 in Rheumatology International
Verified
Journal Article
Open access
PDF file
AMAparna R. Menon
Aparna R. Menon
SCSomy Cherian
Somy Cherian
APAby Paul
Aby Paul
KKKripesh Kumar
Kripesh Kumar
SASakir Ahmed
Sakir Ahmed
PSPadmanabha Shenoy
Padmanabha Shenoy
Patients with autoimmune rheumatic diseases with a previous infection by the SARS-CoV-2 virus have exaggerated responses to a single dose of COVID-19 vaccination as compared to fully vaccinated infection naive patients. The second dose is currently recommended at an extended gap after the infection, but the information available regarding response to the second dose in this subgroup is limited. Patients with AIRDs previously infected with COVID-19, who have received at least one dose of AZD1222/ChAdOx1 (n = 200) were included and stratified based on vaccine doses (V), and infection (I) into I + V, I + V + V, V + I, V + V + I. Anti-RBD (receptor binding domain) antibodies were compared across the four groups. In 49 patients of the I + V + V group (AZD12222), paired sera were compared for antibody levels and neutralization after each vaccine dose. Thirty patients with hybrid immunity after BBV152 and 25 with complete vaccination without infection were included as controls. The highest anti-RBD antibody levels were observed in the V + V + I group (18,219 ± 7702 IU/ml) with statistically similar titers in the I + V + V (10,392 ± 8514 IU/ml) and the I + V (8801 ± 8122 IU/ml). This was confirmed in the 49 paired samples that paradoxically showed a lowering of antibody titers after the second dose [9626 (IQR: 4575–18,785)–5781 (2484–11,906); p < 0.001]. Neutralization of the Delta variant was unaffected but Omicron neutralization was significantly reduced after the second dose [45.7 (5.3–86.53)–35% (7.3–70.9); p = 0.028]. Ancillary analyses showed that only the hybrid immune sera could neutralize the Omicron variant and AZD1222 hybrids performed better than BBV152 hybrids. The second dose of AZD1222 did not boost antibody titers in patients with RD who had COVID-19 previously. In the analysis of paired sera, the second dose led to a statistically significant reduction in antibody titers and also reduced neutralization of the Omicron variant.